Search

for
Search:

GlossaryBRAVE-AA2

clinical trial evaluating baricitinib for severe alopecia areata

BRAVE-AA2 is a clinical trial designed to evaluate the efficacy and safety of a drug called baricitinib for treating alopecia areata, an autoimmune condition that causes hair loss. The trial specifically focuses on adults with severe alopecia areata and aims to determine how well the drug can help regrow hair and improve patients' quality of life.

Related Terms

Research

5 / 1000+ results

research Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies

2 citations , June 2024 in “Journal of the American Academy of Dermatology”

Patients and clinicians generally agree on eyebrow and eyelash hair loss improvements in severe alopecia areata.

research Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2

November 2025 in “SKIN The Journal of Cutaneous Medicine”

Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.

Long-Term Efficacy of Baricitinib in the Treatment of Alopecia Areata: Results at Week 104 from the BRAVE-AA1 and BRAVE-AA2 Studies

research Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2

November 2023 in “Annales de dermatologie et de vénéréologie, FMC”

Baricitinib effectively treats severe alopecia for up to 104 weeks.

Characterization of Scalp, Eyelash, and Eyebrow Hair Regrowth in Patients with Severe Alopecia Areata Randomized to Placebo in BRAVE AA1 and BRAVE AA2 Trials

research Characterization of scalp, eyelash and eyebrow hair regrowth in patients with severe alopecia areata randomized to placebo in brave AA1 and brave AA2 trials

June 2024 in “JEADV Clinical Practice”

Severe alopecia areata patients have a low chance of spontaneous hair regrowth.

Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials

research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)

20 citations , March 2023 in “American Journal of Clinical Dermatology”

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

View more "brave-aa2" in research →

Community Join

3 / 1000+ results

community Brave soldier leading the army

in Satire 327 upvotes 3 years ago

User saw new hair growth after 2 months of treatment. Others shared similar experiences and joked about hair soldiers reclaiming lost territory.

community Eddie Bravo talking about hair loss on JRE

in Satire 325 upvotes 2 years ago

The conversation is about a 53-year-old man's struggle with hair loss and the various perspectives on balding. It also mentions the use of finasteride as a hair loss treatment.

community How to deal with feeling ugly while balding but not brave enough to shave

in Chat 15 upvotes 3 months ago

An 18-year-old is dealing with hair loss and considering minoxidil and finasteride. Suggestions include starting finasteride, saving for a hair transplant, embracing baldness, and focusing on self-improvement.

View more "brave-aa2" in community →

Learn

— no results

Try a deeper search in learn →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →